> 回列表
UBIA Group and Development Center of Biotechnology Co-Develop a New Targeted Cancer Therapy Drug
February 18, 2016
 

UBI Pharma (UBIP; Stock Code 6562) has entered the targeted cancer therapy field after licensing B-Raf kinase inhibitor (UB-941) from Development Center for Biotechnology (DCB).

B-Raf gene mutation is known to play a role in human cancer and has become an important drug target. B-Raf mutation is found in multiple highly metastatic cancers, including melanoma, thyroid cancer, colorectal cancer, non-small cell lung cancer and ovarian cancer. In animal and in vitro studies, the licensed B-Raf kinase inhibitor has shown better efficacy and safety than current marketed B-Raf kinase inhibitor products. Pre-clinical studies and manufacturing process development are complete and UBIP has filed for phase I clinical trial to US FDA.

Since its establishment in 1984, DCB has been bridging academia and industry to accelerate the development of Taiwan’s biotechnology industry, thanks to the efforts of Mr. Guo-Ding Li. DCB licensed its novel anti-HSV mAb drug (UB-621) to UBIA with development continuing at United BioPharma (UBP), a spin-off from UBIA. UBP received grants from Department of Industrial Technology, Ministry of Economic Affairs for its solid CMC development capability that pushed UB-621 to phase I clinical trial. UB-621 is another example of successful academia-industry cooperation.

“New drug developers should always bear a sense of urgency. In addition to the advanced technologies, clinical progress and market trends are equally important” said Dr. Liang-Sheng Gan, the CEO of DCB, “A thorough assessment of drug potential is essential as well.”

“Pharmaceutical development is just like a 400 meters relay race. DCB is the first (drug target discovery) and second (lead optimization, preclinical evaluation) runners, while enterprises are the third and final runners, in charge of CMC development, clinical trials, GMP manufacturing, international registration, and global marketing” said Dr. Chang Yi Wang, Chairperson of UBIP.

“DCB has done an amazing job and UBIP will take over from this point. This cooperation clearly shows us the core technology and value of Taiwan’s biotechnology industry. It also accelerates our new drug development and commercialization, thereby enhancing the competitiveness of Taiwan. I believe the collaboration between DCB and UBIA Group will deliver more new drugs to commercialization and show the world our talents and abilities.”

UBIP’s experience in new drug development and cGMP manufacturing is well recognized and led to winning the bid on licensing this global product rights from DCB.


For more information, please visit http://unitedbiomedical.org/?p=15696#more-15696

About United Biomedical, Inc., Pharma (6562)
UBIP was established in August 2014 as a spin-off company from UBIA, specializing in the development, manufacturing, and marketing of innovative fusion protein drugs and specialty injectables. In addition, UBIP has the only US FDA certified sterile injectable filling line in Asia outside of Japan. UBIP also provides contract development and manufacturing services. For more information, please visit: http://www.ubi-pharma.com

Contact:
Ying-Yun Vivien Fan
Director of Public Relations and Spokesperson
Telephone: 886-3-597-7676 ext. 2113
PR@unitedbiopharma.com

E-mail:vivien.fan@ubi-pharma.com